Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals on $2.5M Registered Direct Offering
August 4, 2015 – Press Release – New York, NY – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biopharmaceutical company focused on developing and commercializing cancer therapies, in a registered direct offering. DelMar accepted subscriptions from institutional and accredited investors and approximately 4.0 million common stock and warrants for an aggregate price of $2.5 million. Each common share had a purchase price of $0.60 per share. The warrants had an exercise price of $0.75 per share.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, David Manno and Associate Jeffrey Cahlon.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Advises US Gold Corp. on $2.5 Million Public Offering - October 13, 2017
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $1.56 Million Shelf Take Down - October 12, 2017
- Sichenzia Ross Ference Kesner LLP Cited as Top-Ranked Legal Counsel for PIPE Issuers in the Third Quarter 2017 - October 3, 2017